News
Gilead signs biotech deal arming T-cells to attack solid tum...
Gilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors that could lead to cell therapies capable of targeting solid tumours.
